Skip to main content
Terug
Watch Compare

BioCorRx Inc.

Datakwaliteit: 100%
BICX
OTC Services Health Services
€ 0,26
▼ € 0,14 (-35,75%)
Marktkapitalisatie: 6,09 M
Prijs
€ 0,26
Marktkapitalisatie
6,09 M
Dagbereik
€ 0,26 — € 0,26
52-Weeksbereik
€ 0,20 — € 0,50
Volume
20
Openen € 0,26
50D / 200D Gem.
€ 0,35
26,23% below
50D / 200D Gem.
€ 0,37
30,43% below

Quick Summary

Belangrijkste Punten

Revenue grew 101,59% annually over 5 years — strong growth
Negative free cash flow of -2,30 M
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 10199,51%

Groei

Revenue Growth (5Y)
101,59%
Boven sectorgemiddelde (4,21%)
Revenue (1Y)10301,10%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
N/A
ROICN/A
Net Margin-431,50%
Op. Margin-606,04%

Veiligheid

Debt / Equity
N/A
Current Ratio0,10
Interest Coverage-21,58

Waardering

PE (TTM)
-1,77
Onder sectorgemiddelde (-1,17)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Services sector mediaan (502 peers)
Metriek Aandeel Sector Mediaan
P/E -1,8 -1,2
P/B — 1,4
ROE % — -15,7
Net Margin % -431,5 -18,3
Rev Growth 5Y % 101,6 4,2
D/E — 0,4

All Fundamental Metrics
Growth
Revenue Growth (1Y) 10301,10% Revenue Growth (3Y) 199,03%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 101,59% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 797.244,0 Net Income (TTM) -3,44 M
ROE N/A ROA -48,40%
Gross Margin N/A Operating Margin -606,04%
Net Margin -431,50% Free Cash Flow (TTM) -2,30 M
ROIC N/A FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 0,10
Interest Coverage -21,58 Asset Turnover 0,11
Working Capital -13,58 M Tangible Book Value -19,34 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -1,77 Forward P/E N/A
P/B Ratio N/A P/S Ratio 7,64
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -37,73%
Market Cap 6,09 M Enterprise Value 6,09 M
Per Share
EPS (Diluted TTM) -0,19 Revenue / Share 0,03
FCF / Share -0,10 OCF / Share -0,10
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 66,81%
SBC-Adj. FCF -2,74 M Growth Momentum 10199,51

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 797.244,0 7.665,0 89.160,0 213.841,0 48.272,0
Net Income -3,44 M -5,21 M -3,77 M -4,38 M -5,21 M
EPS (Diluted) -0,19 — — — —
Gross Profit — — — — —
Operating Income -4,83 M -5,12 M -3,79 M -4,70 M -5,51 M
EBITDA — — — — —
R&D Expenses 1,77 M 1,48 M 891.063,0 1,46 M 1,61 M
SG&A Expenses 3,79 M 3,61 M 2,88 M 3,41 M —
D&A 44.003,0 33.145,0 26.808,0 27.450,0 64.328,0
Interest Expense 223.850,0 776.780,0 194.041,0 150.969,0 -565.684,0
Income Tax 0,0 0,0 0,0 0,0 0,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 2,15 M 385.941,0 388.887,0 766.594,0 819.975,0
Total Liabilities 13,67 M 12,74 M 10,34 M 8,97 M 7,78 M
Shareholders' Equity -11,22 M -12,12 M -9,82 M -8,20 M -6,84 M
Total Debt — — — 0,0 —
Cash & Equivalents — — — — 592.053,0
Current Assets 814.468,0 117.996,0 187.119,0 316.910,0 228.326,0
Current Liabilities 8,31 M 8,21 M 6,43 M 5,36 M 4,39 M